Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and
Chiara Arienti1, Sara Pignatta1, Michele Zanoni1
1Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS.
Abstract:
The past two decades have seen a shift from cytotoxic drugs to targeted therapy in medical oncology. Although targeted therapeutic agents have shown more impressive clinical efficacy and minimized adverse effects than traditional treatments, drug resistance has become the main limitation to their benefits. Several preclinical in vitro/in vivo models of acquired resistance to targeted agents in clinical practice have been developed mainly by using two strategies: i) genetic manipulation for modeling genotypes of acquired resistance, and ii) in vitro/in vivo selection of resistant models. In the present work, we propose a unifying framework, for investigating the underlying mechanisms responsible for acquired resistance to targeted therapeutic agents, starting from the generation of drug-resistant cellular subclones to the description of silencing procedures used for restoring the sensitivity to the inhibitor. This simple time- and cost-effective approach is widely applicable, and could be easily extended to investigate resistance mechanisms to other targeted therapeutic drugs in different tumor histotypes.
Insights
Researchers developed a cost-effective framework to study drug resistance in targeted cancer therapy. This approach helps understand and potentially overcome acquired resistance, improving treatment efficacy.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- The shift from cytotoxic drugs to targeted therapy in oncology has improved efficacy but faces challenges with drug resistance.
- Acquired resistance to targeted agents is a major limitation in cancer treatment.
- Current preclinical models for studying resistance involve genetic manipulation or in vitro/in vivo selection.
Purpose of the Study:
- To propose a unifying framework for investigating the mechanisms of acquired resistance to targeted therapeutic agents.
- To provide a method for generating drug-resistant cellular subclones and restoring sensitivity to inhibitors.
- To offer a widely applicable and cost-effective approach for studying resistance mechanisms.
Main Methods:
- Development of a novel framework for studying acquired resistance to targeted therapy.
- Generation of drug-resistant cellular subclones.
- Description of silencing procedures to restore sensitivity to targeted inhibitors.
Main Results:
- The proposed framework offers a simple, time- and cost-effective method for investigating resistance mechanisms.
- The approach is widely applicable across different targeted therapeutic drugs and tumor histotypes.
- This methodology facilitates the study of acquired resistance from initial resistance development to sensitivity restoration.
Conclusions:
- The developed framework provides a comprehensive and efficient approach to study acquired resistance to targeted cancer therapies.
- This method can be extended to investigate resistance mechanisms for various targeted drugs and cancer types.
- Understanding and overcoming drug resistance is crucial for enhancing the long-term benefits of targeted cancer therapy.
Related Concept Videos
Resistivity
Resistance
Gene Therapy
Equivalent Resistance
Resistance and Conductance
Various factors impact the resistance of a conductor. Spiraling in stranded conductors increases their...
Rolling Resistance
For instance, imagine a hard cylinder rolling on a comparatively soft surface. The cylinder's weight compresses the surface beneath it. As the cylinder moves, the material in front of it slows down due to...


